Show simple item record

dc.contributor.authorSavina, M
dc.contributor.authorLitiere, S
dc.contributor.authorItaliano, A
dc.contributor.authorBurzykowski, T
dc.contributor.authorBonnetain, F
dc.contributor.authorGourgou, S
dc.contributor.authorRondeau, V
dc.contributor.authorBlay, JY
dc.contributor.authorCousin, S
dc.contributor.authorDuffaud, F
dc.contributor.authorGelderblom, H
dc.contributor.authorGronchi, A
dc.contributor.authorJudson, I
dc.contributor.authorLe, CA
dc.contributor.authorLorigan, Paul C
dc.contributor.authorMaurel, J
dc.contributor.authorvan der Graaf, W
dc.contributor.authorVerweij, J
dc.contributor.authorMathoulin-Pelissier, S
dc.contributor.authorBellera, C
dc.date.accessioned2018-12-05T10:35:49Z
dc.date.available2018-12-05T10:35:49Z
dc.date.issued2018en
dc.identifier.citationSavina M, Liti�re S, Italiano A, Burzykowski T, Bonnetain F, Gourgou S, et al. Surrogate endpoints in advanced sarcoma trials: a meta-analysis. Oncotarget. 2018 Sep 18;9(77).en
dc.identifier.pmid30349653en
dc.identifier.doi10.18632/oncotarget.26166en
dc.identifier.urihttp://hdl.handle.net/10541/621353
dc.description.abstractBACKGROUND: Alternative endpoints to overall survival (OS) are frequently used to assess treatment efficacy in randomized controlled trials (RCT). Their properties in terms of surrogate outcomes for OS need to be assessed. We evaluated the surrogate properties of progression-free survival (PFS), time-to-progression (TTP) and time-to-treatment failure (TTF) in advanced soft tissue sarcomas (STS). RESULTS: A total of 21 trials originally met the selection criteria and 14 RCTs (N = 2846) were included in the analysis. Individual-level associations were moderate (highest for 12-month PFS: Spearman's rho = 0.66; 95% CI [0.63; 0.68]). Trial-level associations were ranked as low for the three endpoints as per the IQWiG criterion. MATERIALS AND METHODS: We performed a meta-analysis using individual-patient data (IPD). Phase II/III RCTs evaluating therapies for adults with advanced STS were eligible. We estimated the individual- and the trial-level associations between then candidate surrogates and OS. Statistical methods included weighted linear regression and the two-stage model introduced by Buyse and Burzykowski. The strength of the trial-level association was ranked according to the German Institute for Quality and Efficiency in Health Care (IQWiG) guidelines. CONCLUSIONS: Our results do not support strong surrogate properties of PFS, TTP and TTF for OS in advanced STS.en
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.18632/oncotarget.26166en
dc.titleSurrogate endpoints in advanced sarcoma trials: a meta-analysisen
dc.typeArticleen
dc.contributor.departmentClinical and Epidemiological Research Unit, Institut Bergonie, Comprehensive Cancer Center, Bordeaux cedex 33076, Franceen
dc.identifier.journalOncotargeten
dc.description.noteen]


This item appears in the following Collection(s)

Show simple item record